Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.63 |
| ▸ | BRD2 | P25440 | 1/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.63 |
| ▸ | TSPO | P30536 | 1/20 | 0.63 |
| ▸ | EP300 | Q09472 | 1/20 | 0.63 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.63 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23983931 | 0.94 | BRD4 (0.71) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL23983927 | 0.92 | BRD4 (0.58) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL23983934 | 0.90 | BRD4 (0.60) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL25656280 | 0.89 | BRD4 (0.71) | BRD4BRD2BRD3BRDT | |
| SCHEMBL25656283 | 0.88 | BRD4 (0.57) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL23983932 | 0.88 | BRD4 (0.53) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL16650588 | 0.86 | BRD4 (0.69) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL25656279 | 0.85 | BRD4 (0.74) | BRD4 | |
| SCHEMBL23983928 | 0.85 | BRD4 (0.59) | BRD4BRDT | |
| SCHEMBL23984418 | 0.84 | BRD4 (0.74) | BRD4BRD2BRD3BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174545-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2023-06-08 | — | — | US | disclosed |
| US-20230174545-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174545-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | BET1, BRD4, BRD3 | BRD4 2/4885BRD2 5/4885ADORA2B 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.